See also this year's filing and all EDGAR filings for this company.
PDF Report 0001556263_2021_Syros_Pharmaceuticals_Inc.pdf
Logs
| warning | The stock price does not exist | industry.us_generic | {} |
| info | NetIncome node detected by revenue/expenses heuristic | input.sec.calculation_linkbase.edgar_model_mapping | {'net_inc_node': 'OperatingIncomeLoss'} |
Graph
Absolute values for 0001556263, Syros Pharmaceuticals Inc
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 178,557,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 14,213,000 |
| 3 | remainder_Assets | 20,480,000 |
| 4 | LiabilitiesCurrent | 28,624,000 |
| 5 | LiabilitiesNoncurrent | 0 |
| 6 | remainder_Liabilities | 0 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 21,241,191 |
| 9 | ResearchAndDevelopmentExpense | 82,068,142 |
| 10 | remainder_Expenses | 0 |
| 11 | remainder_Revenues | 12,510,236 |
| 12 | remainder_NetIncome | 0 |
| 13 | remainder_ComprehensiveNetIncome | 2,325,658 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 213,250,000 |
| 1 | Liabilities | 28,624,000 |
| 2 | Expenses | 103,309,333 |
| 3 | Revenues | 12,510,236 |
| 4 | StockholdersEquity | 184,626,000 |
| 5 | NetIncome | -90,799,097 |
| 6 | ComprehensiveNetIncome | -89,636,268 |
| 7 | BaseVar | 180,009,614 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | 2.59 |
| 9 | EconomicCapitalRatio | 3.41 |
Edgar->Model Mapping
Feature Distribution
Change over Time
